FAP and neoplasm: Although glofitamab induced a nonsignificant increase in tumor cell death, its pairing with either FAP-IL2v or FAP-4-1BBL resulted in augmented DLBCL cell death compared with untargeted control drugs in all the lymphoma tissues tested — suggesting that the levels and distribution of FAP in human DLBCL is sufficient to enable target-mediated costimulation of interacting TILs (Figure 12D) (Supplemental Figure 9, C–G).